Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Comparison of the Clinical Outcomes of Nilotinib and Dasatinib Therapies in Newly Diagnosed Patients in the Chronic Phase of Chronic Myeloid Leukemia: A Retrospective Analysis

Noriyoshi Iriyama, MD PhD, Kei-Ji Sugimoto, Eriko Sato, MD PhD, Tomoiku Takaku, MD PhD, Michihide Tokuhira, Tomonori Nakazato, MD PhD, Maho Ishikawa, MD, Hiroyuki Fujita, MD PhD, Yuta Kimura, MD, Isao Fujioka, MD, Norio Asou, MD PhD, Masahiro Kizaki, MD PhD, Norio Komatsu, MD PhD, Yoshihiro Hatta, MD PhD, Tatsuya Kawaguchi, MD PhD

Blood (2018) 132 (Supplement 1): 4268.

https://doi.org/10.1182/blood-2018-99-111732

Published: 2018

Journal Articles

Optimal Treatment Strategy with Nilotinib for Patients with Newly Diagnosed Chronic Myelogenous Leukemia in the Chronic Phase Based on Early Achievement of Deep Molecular Response (MR 4.5 ) : First Report from N-Road, a Phase II Study in Japan

Kaichi Nishiwaki, MD PhD, Kei-Ji Sugimoto, MD PhD, Shigehisa Tamaki, MD PhD, Junichi Hisatake, MD PhD, Hisayuki Yokoyama, MD PhD, Tadahiko Igarashi, MD PhD, Atsushi Shinagawa, MD PhD, Takeaki Sugawara, MD PhD, Satoru Hara, MD PhD, Kazuhisa Fujikawa, MD PhD, Seiichi Shimizu, MD PhD, Yujiri Toshiaki, MD PhD, Arinobu Tojo, MD PhD, Hisashi Wakita, MD PhD

Blood (2016) 128 (22): 1925.

https://doi.org/10.1182/blood.V128.22.1925.1925

Published: 2016

Journal Articles

Clinical Entity and Outcomes of Therapy-Related Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: Surveillance By the Chronic Myeloid Leukemia Cooperative Study Group

Noriyoshi Iriyama, MDPhD, Tomoiku Takaku, MD, PhD, Eriko Sato, Maho Ishikawa, Tomonori Nakazato, Kei-Ji Sugimoto, MD PhD, Hiroyuki Fujita, MD PhD, Michihide Tokuhira, MD PhD, Tatsuya Kawaguchi, MD PhD

Blood (2016) 128 (22): 3084.

https://doi.org/10.1182/blood.V128.22.3084.3084

Published: 2016

Journal Articles

Impact of Ph+ Stem Cell Burden on Clinical Findings and Molecular Responses to First-Line Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia: The Results from the Interim Analysis of N-Road, Multi-Center a Phase II Study

Mayuko Tsuda, MD, Kaichi Nishiwaki, MD PhD, Kei-ji Sugimoto, MD PhD, Hisayuki Yokoyama, MD PhD, Tadahiko Igarashi, MD PhD, Seiichi Shimizu, MD PhD, Toshiaki Yujiri, MD PhD, Hisashi Wakita, MD PhD, Arinobu Tojo, MD PhD

Blood (2014) 124 (21): 3159.

https://doi.org/10.1182/blood.V124.21.3159.3159

Published: 2014

Journal Articles

t(6;14)(p22;q32): a new recurrent IGH@ translocation involving ID4 in B-cell precursor acute lymphoblastic leukemia (BCP-ALL)

Lisa J. Russell, Takashi Akasaka, Aneela Majid, Kei-ji Sugimoto, E. Loraine Karran, Inga Nagel, Lana Harder, Alexander Claviez, Stefan Gesk, Anthony V. Moorman, Fiona Ross, Helen Mazzullo, Jonathan C. Strefford, Reiner Siebert, Martin J. S. Dyer, Christine J. Harrison

Blood (2008) 111 (1): 387–391.

https://doi.org/10.1182/blood-2007-07-092015

Published: 2008

Journal Articles

Five members of the CEBP transcription factor family are targeted by recurrent IGH translocations in B-cell precursor acute lymphoblastic leukemia (BCP-ALL)

Blood (2006) 109 (8): 3451–3461.

https://doi.org/10.1182/blood-2006-08-041012

Published: 2006

Includes: Supplemental data

Journal Articles

Homozygous deletions localize novel tumor suppressor genes in B-cell lymphomas

Blood (2006) 109 (1): 271–280.

https://doi.org/10.1182/blood-2006-06-026500

Published: 2006

Includes: Supplemental data

Journal Articles

Involvement of the CEBP Gene Family in Four IGH@ Chromosomal Translocations in B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL).

Martin J.S. Dyer, MD, PhD, Takashi Akasaka, MD, PhD, Theodore Balasas, BSc, Lisa Russell, BSc, Kei-Ji Sugimoto, MD, PhD, Aneela Majid, PhD, David G. Brown, BSc, Kelvin Cain, PhD, Jon C. Strefford, PhD, Christine J. Harrison, PhD, Reiner Siebert, MD, PhD

Blood (2005) 106 (11): 2842.

https://doi.org/10.1182/blood.V106.11.2842.2842

Published: 2005

NARROW

Comparison of the Clinical Outcomes of Nilotinib and Dasatinib Therapies in Newly Diagnosed Patients in the Chronic Phase of Chronic Myeloid Leukemia: A Retrospective Analysis

Optimal Treatment Strategy with Nilotinib for Patients with Newly Diagnosed Chronic Myelogenous Leukemia in the Chronic Phase Based on Early Achievement of Deep Molecular Response (MR 4.5 ) : First Report from N-Road, a Phase II Study in Japan

Clinical Entity and Outcomes of Therapy-Related Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: Surveillance By the Chronic Myeloid Leukemia Cooperative Study Group

Impact of Ph+ Stem Cell Burden on Clinical Findings and Molecular Responses to First-Line Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia: The Results from the Interim Analysis of N-Road, Multi-Center a Phase II Study

t(6;14)(p22;q32): a new recurrent IGH@ translocation involving ID4 in B-cell precursor acute lymphoblastic leukemia (BCP-ALL)

Five members of the CEBP transcription factor family are targeted by recurrent IGH translocations in B-cell precursor acute lymphoblastic leukemia (BCP-ALL)

Homozygous deletions localize novel tumor suppressor genes in B-cell lymphomas

Involvement of the CEBP Gene Family in Four IGH@ Chromosomal Translocations in B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only